Dulaglutide (brand name Trulicity) is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for treating type 2 diabetes mellitus. It works by stimulating insulin secretion, delaying gastric emptying, and increasing satiety, which leads to improved glycemic control and weight reduction. Clinical trials have demonstrated its efficacy in lowering HbA1c levels, reducing body weight, and potentially providing cardiovascular benefits.

Overview

Dulaglutide, marketed under the brand name Trulicity, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and approved by the FDA in 2014 for the treatment of type 2 diabetes mellitus. The molecule consists of a modified GLP-1 analog covalently linked to a modified immunoglobulin G4 (IgG4) Fc fragment, which extends its half-life to approximately five days and enables convenient once-weekly subcutaneous dosing.

Dulaglutide works by mimicking the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying, and promoting satiety. In clinical trials across the AWARD program, dulaglutide demonstrated significant reductions in hemoglobin A1c (HbA1c) ranging from 0.7% to 1.6%, along with modest weight loss. The landmark REWIND trial further established that dulaglutide reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, including those without established cardiovascular disease.

Dulaglutide is available in pre-filled, single-use pens at doses of 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg for weekly injection. The most common side effects are gastrointestinal, including nausea, diarrhea, and vomiting, which typically diminish over time. As with all GLP-1 receptor agonists, dulaglutide carries a boxed warning regarding the risk of medullary thyroid carcinoma based on rodent studies, and it is contraindicated in patients with a personal or family history of this condition or multiple endocrine neoplasia type 2.

Mechanism of Action

"

GLP-1 Receptor Agonism — Incretin Mimetic\n\nDulaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) consisting of a modified GLP-1(7-36) analog covalently linked to a modified human IgG4 Fc fragment via a small peptide linker. The GLP-1 analog component contains amino acid substitutions (Ala8Gly to resist DPP-4 cleavage, Gly36 replacement) that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation while maintaining full agonist activity at the GLP-1 receptor (GLP-1R). The Fc fusion increases the hydrodynamic radius, reducing renal clearance and yielding a half-life of approximately 5 days, enabling once-weekly dosing (PMID: 25488693).\n\n

Pancreatic Beta-Cell Signaling\n\nDulaglutide binds the GLP-1R, a class B G protein-coupled receptor (GPCR), on pancreatic beta-cells. Receptor activation stimulates Gas → adenylyl cyclase → cAMP → PKA/Epac2 signaling cascades that potentiate glucose-stimulated insulin secretion (GSIS) by closing KATP channels, depolarizing the beta-cell membrane, and enhancing L-type Ca2+ channel-mediated calcium influx for insulin granule exocytosis. Critically, this insulinotropic effect is glucose-dependent — at euglycemia, the cAMP potentiation is insufficient to trigger secretion, minimizing hypoglycemia risk. Dulaglutide also suppresses glucagon secretion from alpha-cells through both direct GLP-1R-mediated inhibition and paracrine insulin/somatostatin signaling (PMID: 24843537).\n\n

Extrapancreatic Metabolic and Cardiovascular Effects\n\nIn the hypothalamus, dulaglutide activates GLP-1R on POMC/CART neurons in the arcuate nucleus, promoting satiety signaling and reducing food intake. It simultaneously inhibits NPY/AgRP orexigenic neurons, producing sustained appetite suppression and weight loss of 2–5 kg over 26 weeks. Gastric GLP-1R activation delays gastric emptying by 20–30%, further reducing postprandial glucose excursions. Cardiovascularly, GLP-1R signaling in cardiomyocytes activates PI3K/Akt and AMPK pathways, improving myocardial glucose uptake, reducing ischemia-reperfusion injury, and exerting anti-atherosclerotic effects through decreased endothelial VCAM-1/ICAM-1 expression. The REWIND trial demonstrated a 12% reduction in major adverse cardiovascular events (MACE) with dulaglutide (PMID: 31189511)."

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Dulaglutide (FDA Approved)

Overview Dulaglutide (brand name Trulicity) is an FDA-approved GLP-1 receptor agonist indicated for type 2 diabetes mellitus and cardiovascular risk reduction. Administered as a once-weekly subcutaneous injection, it has been extensively studied in the REWIND cardiovascular outcomes trial and the AWARD clinical program. Its safety profile is well-characterized with gastrointestinal effects being predominant.

Common Side Effects

• Nausea (12-21%), the most common side effect, usually dose-dependent and diminishing over 2-4 weeks
• Diarrhea (8-12%) and vomiting (6-12%)
• Abdominal pain and dyspepsia (6-9%)
• Decreased appetite (contributing to weight loss of 2-5 kg on average)
• Injection site reactions: erythema, itching, and induration (1-2%)
• Fatigue and asthenia

Serious Adverse Effects

• Pancreatitis: acute pancreatitis reported in clinical trials and post-marketing; discontinue immediately if suspected. Patients with history of pancreatitis should use with extreme caution
• Medullary thyroid carcinoma (MTC): carries FDA Black Box Warning based on rodent studies showing thyroid C-cell tumors; contraindicated in patients with personal or family history of MTC or MEN2
• Hypoglycemia: low risk as monotherapy but significantly increased when combined with insulin or sulfonylureas
• Acute kidney injury: reported in patients with dehydration from severe GI side effects (nausea, vomiting, diarrhea)
• Diabetic retinopathy complications: may worsen in patients with pre-existing retinopathy during rapid glucose improvement
• Gallbladder events: cholelithiasis and cholecystitis reported at higher rates than placebo

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to dulaglutide (anaphylaxis and angioedema reported)
• History of severe pancreatitis
• Type 1 diabetes or diabetic ketoacidosis (not indicated)
• Severe gastrointestinal disease (gastroparesis) as GLP-1 agonists delay gastric emptying

Drug Interactions

• Insulin and sulfonylureas: increased hypoglycemia risk; dose reduction of these agents is typically needed
• Oral medications with narrow therapeutic windows (warfarin, digoxin): delayed gastric emptying may alter absorption kinetics; monitor drug levels
• Oral contraceptives: absorption may be affected by delayed gastric emptying; take at least 1 hour before dulaglutide
• Acetaminophen and antibiotics: Cmax may be reduced due to delayed gastric emptying

Special Populations

• Renal impairment: no dose adjustment needed for mild-to-moderate; caution in severe (eGFR < 15) due to limited data
• Hepatic impairment: no dose adjustment needed
• Pregnancy Category C: not recommended; discontinue at least 2 months before planned pregnancy
• Not approved for pediatric use under age 10

Dosage Considerations

• Starting dose: 0.75 mg subcutaneously once weekly
• May titrate to 1.5 mg, 3.0 mg, and maximum 4.5 mg once weekly
• Administer any day of the week, with or without food

Pharmacokinetic Profile